A Randomized, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Single And Multiple Ascending Dose Study To Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Bioavailability and Food Effect (Open-Label) of Sage-319 in Healthy Adult Participants.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512987-74-00

Acronym

CHDR2239

Enrollment

104

Registered

2024-05-02

Start date

2023-02-27

Completion date

2025-10-10

Last updated

2024-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disorders characterized by a deficit in GABAergic signaling and cerebellar circuitry.

None listed

Sex/Gender

All

Age

18 Years to No maximum

Netherlands

None listed

Source: EU CTIS · Data processed: Feb 4, 2026